Images List Premium Download Classic

Alcoholic Fatty Liver

Alcoholic Fatty Liver-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of ...
Sancilio & Company, Inc.
September 14, 2017 - N°20170258752

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either ...
Cenicriviroc for the treatment of fibrosis
Tobira Therapeutics ,inc.
August 24, 2017 - N°20170239262

The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (...
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
Somalogic, Inc.
August 10, 2017 - N°20170227550

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (nash) are also provided.
Alcoholic Fatty Liver Patent Pack
Download + patent application PDFs
Alcoholic Fatty Liver Patent Applications
Download + Alcoholic Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Alcoholic Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Prevention and treatment of non-alcoholic fatty liver disease
Ohio University
July 13, 2017 - N°20170196845

Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue. The methods include administering to the subject or contacting the liver tissue with a therapeutically effective ...
Inhibitors of the farnesoid x receptor and uses in medicine
The Penn State Research Foundation
June 01, 2017 - N°20170152283

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier ...
Calcitonin mimetics for treating diseases and disorders
The Penn State Research Foundation
May 25, 2017 - N°20170143800

Calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues ...
Alcoholic Fatty Liver Patent Pack
Download + patent application PDFs
Alcoholic Fatty Liver Patent Applications
Download + Alcoholic Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Alcoholic Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
Gw Pharma Limited
May 11, 2017 - N°20170128385

The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (nafld), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of ...
Thyromimetics for the treatment of fatty liver diseases
Metabasis Therapeutics, Inc.
April 27, 2017 - N°20170112864

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Composition for preventing and treating non-alcoholic fatty liver diseases
Jbk Natural Medicine Institute
April 20, 2017 - N°20170106035

A composition includes a black chokeberry extract and at least one of a thistle extract, a black hoof mushroom extract and a mixture thereof. The composition is effective in preventing and treating non-alcoholic fatty liver disease caused by accumulation of fat in the liver due to excessive intake of nutrients or metabolic syndrome regardless of alcohol intake. The composition can ...
Method and system for treating non-alcoholic fatty liver disease
Jbk Natural Medicine Institute
April 20, 2017 - N°20170106026

A method and system for treating non-alcoholic fatty liver disease (nafld) involves the modulation of the gut microbial of a person suffering from nafld, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, tnf-α and to improve insulin resistance in nafld patients.
Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
Hadasit Medical Research Services And Development Ltd.
April 20, 2017 - N°20170105996

Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
Novartis Ag
March 09, 2017 - N°20170065678

The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e. G. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, ...
Alcoholic Fatty Liver Patent Pack
Download + patent application PDFs
Alcoholic Fatty Liver Patent Applications
Download + Alcoholic Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Alcoholic Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver ...
Snu R&db Foundation
February 23, 2017 - N°20170049773

The present invention relates to a pharmaceutical composition containing a g protein coupled receptor 119 (gpr119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the gpr119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways ...
Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
February 09, 2017 - N°20170037043

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their ...
Systems, devices and methods for performing medical procedures in the intestine
Fractyl Laboratories, Inc.
January 12, 2017 - N°20170007310

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element. The catheter is introduced ...
Method for assessment of hepatic function and portal blood flow
The Regents Of The University Of Colorado, A Body Corporate
December 29, 2016 - N°20160377594

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the stat test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, ...
Modulation of nlgn4 expression, nk cell activity in non-alcoholic fatty liver disease (nafld)
Hadasit Medical Research Services And Development Ltd.
December 22, 2016 - N°20160369347

The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an nlgn4 gene product in the immune cell population using nlgn4 specific primers or nlgn4 specific probes.
Glucagon and glp-1 co-agonist compounds
Eli Lilly And Company
December 22, 2016 - N°20160368960

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).
Lysosomal acid lipase therapy for nafld and related diseases
Children's Hospital Medical Center
December 22, 2016 - N°20160367645

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for ...
Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver ...
Universitat Autònome De Barcelona
December 08, 2016 - N°20160354489

The present invention relates to the field of gene therapy and, more particularly, to methods for the prevention and/or treatment of non-alcoholic fatty liver disease (nafld). The viral vectors disclosed in the present invention are preferably parvoviral vector, more preferably adeno-associated vectors (aav) containing the gene encoding sirtuin 1 (sirt1) in the prevention and/or treatment of nafld. The present ...
Loading